[go: up one dir, main page]

FR3077574B1 - Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations. - Google Patents

Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations. Download PDF

Info

Publication number
FR3077574B1
FR3077574B1 FR1851026A FR1851026A FR3077574B1 FR 3077574 B1 FR3077574 B1 FR 3077574B1 FR 1851026 A FR1851026 A FR 1851026A FR 1851026 A FR1851026 A FR 1851026A FR 3077574 B1 FR3077574 B1 FR 3077574B1
Authority
FR
France
Prior art keywords
directed against
antibodies directed
receptor subtype
endothelin receptor
against endothelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1851026A
Other languages
English (en)
Other versions
FR3077574A1 (fr
Inventor
Frederic Ducancel
Didier Boquet
Amaury Herbet
Narciso Costa
Jean-Yves Couraud
Jean-Philippe Hugnot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Universite Paris Cite
Original Assignee
Commissariat a lEnergie Atomique CEA
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to FR1851026A priority Critical patent/FR3077574B1/fr
Priority to EP19744751.9A priority patent/EP3735428A2/fr
Priority to PCT/FR2019/050245 priority patent/WO2019155151A2/fr
Priority to US16/967,763 priority patent/US12084505B2/en
Priority to JP2020542857A priority patent/JP7456930B2/ja
Publication of FR3077574A1 publication Critical patent/FR3077574A1/fr
Application granted granted Critical
Publication of FR3077574B1 publication Critical patent/FR3077574B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des anticorps dirigés contre le sous-type A des récepteurs aux endothélines notamment monoclonaux, un fragment ou un dérivé de ceux-ci. La présente invention concerne également l'utilisation thérapeutique, diagnostique ou comme outil de recherche d'un tel anticorps dans le domaine des cancers et notamment du glioblastome.
FR1851026A 2018-02-07 2018-02-07 Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations. Active FR3077574B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1851026A FR3077574B1 (fr) 2018-02-07 2018-02-07 Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations.
EP19744751.9A EP3735428A2 (fr) 2018-02-07 2019-02-04 Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations
PCT/FR2019/050245 WO2019155151A2 (fr) 2018-02-07 2019-02-04 Anticorps dirigé contre le sous-type a des récepteurs aux endothélines et ses utilisations
US16/967,763 US12084505B2 (en) 2018-02-07 2019-02-04 Antibody against the endothelin receptor subtype A, and uses thereof
JP2020542857A JP7456930B2 (ja) 2018-02-07 2019-02-04 エンドセリン受容体サブタイプａに対する抗体及びその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1851026 2018-02-07
FR1851026A FR3077574B1 (fr) 2018-02-07 2018-02-07 Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations.

Publications (2)

Publication Number Publication Date
FR3077574A1 FR3077574A1 (fr) 2019-08-09
FR3077574B1 true FR3077574B1 (fr) 2022-04-01

Family

ID=62017513

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1851026A Active FR3077574B1 (fr) 2018-02-07 2018-02-07 Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations.

Country Status (5)

Country Link
US (1) US12084505B2 (fr)
EP (1) EP3735428A2 (fr)
JP (1) JP7456930B2 (fr)
FR (1) FR3077574B1 (fr)
WO (1) WO2019155151A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165823A2 (fr) * 2023-02-09 2024-08-15 Commissariat A L'energie Atomique Et Aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2009526861A (ja) * 2006-02-14 2009-07-23 ゲイシンガー クリニック 血管新生標的としてのｇｐｃｒ
JP2008280266A (ja) * 2007-05-09 2008-11-20 Sekisui Chem Co Ltd モノクローナル抗体
FR2965810B1 (fr) 2010-10-06 2012-12-28 Commissariat Energie Atomique Anticorps antagoniste du sous-type b des recepteurs aux endothelines et ses utilisations
CN103728454B (zh) * 2012-10-10 2016-05-18 吴庄民 基于表位抗原肽的抗内皮素受体a抗体酶联免疫试剂盒及其应用
CN111018987B (zh) * 2014-12-05 2023-11-21 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
TWI826351B (zh) * 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
FR3053042B1 (fr) 2016-06-24 2018-08-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations

Also Published As

Publication number Publication date
FR3077574A1 (fr) 2019-08-09
WO2019155151A3 (fr) 2019-12-12
US12084505B2 (en) 2024-09-10
US20220089755A1 (en) 2022-03-24
EP3735428A2 (fr) 2020-11-11
JP2021513345A (ja) 2021-05-27
WO2019155151A2 (fr) 2019-08-15
JP7456930B2 (ja) 2024-03-27

Similar Documents

Publication Publication Date Title
MA34524B1 (fr) Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
MA31984B1 (fr) Formulation d'anticorps
MA38632A1 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
MA34749B1 (fr) Anticorps anti-récepteur de la barrière hémato-encéphalique à faible affinité et leurs utilisations
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
WO2018236870A3 (fr) Procédés et compositions pour le ciblage de cellules cancéreuses avec un récepteur antigénique chimérique
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
SG10201914119TA (en) Anti-b7-h3 antibodies and antibody drug conjugates
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA33551B1 (fr) Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants
MA39061A1 (fr) Modulateurs d'aplnr et leurs utilisations
MA32566B1 (fr) Anticorps neutralisant les cytomégalovirus humains et leurs utilisations
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MA35928B1 (fr) Thérapie combinée d'anticorps contre le csf -1r humain et ses utilisations
MA32561B1 (fr) Anticorps neutralisant le cytomegalovirus humain et leurs utilisations
MA30922B1 (fr) Anticorps d'agonistes de trkb et leurs utilisations
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
MA44665B1 (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
MA43717B1 (fr) Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
WO2007033140A3 (fr) Antagonistes prok2 et leurs procedes d'utilisation
MA44909A (fr) Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20190809

TQ Partial transmission of property

Owner name: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERG, FR

Effective date: 20191217

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20191217

Owner name: UNIVERSITE DE MONTPELLIER, FR

Effective date: 20191217

Owner name: UNIVERSITE PARIS-DIDEROT - PARIS 7, FR

Effective date: 20191217

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

CD Change of name or company name

Owner name: UNIVERSITE PARIS CITE, FR

Effective date: 20230621

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20230621

Owner name: UNIVERSITE DE MONTPELLIER, FR

Effective date: 20230621

Owner name: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERG, FR

Effective date: 20230621

TQ Partial transmission of property

Owner name: UNIVERSITE PARIS CITE, FR

Effective date: 20230621

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20230621

Owner name: UNIVERSITE DE MONTPELLIER, FR

Effective date: 20230621

Owner name: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERG, FR

Effective date: 20230621

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8